ArticleJBMR plus2025
Sodium-glucose co-transporter-2 inhibitors vs metformin in reducing osteoarthritis risk: a retrospective cohort study of health insurance claims and check-up data.
Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Research progress on immune microenvironment imbalance and targeted interventions in osteoarthritis comorbid with diabetes mellitus].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Review
- Oral bisphosphonates and risk of incident osteoarthritis in individuals with osteoporosis: a target trial emulation.RMD open · 2026Article
- Empagliflozin Alleviates Osteoarthritis Progression by Attenuating Inflammation, Restoring Impaired Autophagy, and Ameliorating Chondrocyte Senescence.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to compare the incidence of osteoarthritis between individuals receiving metformin, the most common anti-hyperglycemic drug, and sodium-glucose co-transporter-2 inhibitors (SGLT-2is). This new-user comparative effectiveness study included individuals aged ≥40 yr in the DeSC claims database (DeSC Healthcare Inc.), with health check-up data from April 2014 to August 2023. Individuals initiated on SGLT-2is were compared with those who were initiated on metformin. The primary outcome was knee osteoarthritis, and the secondary outcomes were hip and hand osteoarthritis. After propensity score matching, Cox proportional hazards models were fitted to estimate hazard ratios (HRs) and 95% CIs. In total, 37 171 individuals were included in the study. Of these, 19 216 (68%) were male, and the mean age was 67 yr (SD, 11 yr). After propensity-score matching, the HRs for incident osteoarthritis with SGLT-2is compared with metformin were 1.03 (95% CI: 0.89-1.19) for the knee, 0.95 (95% CI: 0.63-1.43) for the hip, and 1.38 (95% CI: 0.92-2.07) for the hand. Considering the risk of developing osteoarthritis, SGLT-2is may be a viable alternative to metformin for individuals with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.